2012
Pseudomonas aeruginosa serology and risk for re-isolation in the EPIC trial
Anstead M, Heltshe SL, Khan U, Barbieri JT, Langkamp M, Döring G, Dharia S, Gibson RL, Treggiari MM, Lymp J, Rosenfeld M, Ramsey B. Pseudomonas aeruginosa serology and risk for re-isolation in the EPIC trial. Journal Of Cystic Fibrosis 2012, 12: 147-153. PMID: 22944725, PMCID: PMC3696392, DOI: 10.1016/j.jcf.2012.08.001.Peer-Reviewed Original ResearchConceptsPulmonary exacerbationsCF patientsP. aeruginosa eradicationP. aeruginosa isolationCystic fibrosis patientsEarly P. aeruginosaBaseline seropositivityEPIC trialPositive serologyAntibiotic therapyChild TrialTreatment failurePrognostic valuePseudomonas infectionWeek 10Fibrosis patientsSerologyCulture resultsPatientsClinicians' effortsExacerbationSeropositivityP. aeruginosaRiskTrials
2002
Postmenopausal hormone use and skeletal fracture: does the size of the benefit decrease with increasing age?
Weiss NS, Treggiari MM. Postmenopausal hormone use and skeletal fracture: does the size of the benefit decrease with increasing age? Obstetrics And Gynecology 2002, 100: 364-8. PMID: 12151165, DOI: 10.1016/s0029-7844(02)02046-x.Peer-Reviewed Original ResearchConceptsLong-term hormone useOlder postmenopausal womenPostmenopausal womenHormone useFracture riskYounger postmenopausal womenPostmenopausal hormone useSurrogate end pointsBone mineral densityUse of hormonesHormone therapySkeletal benefitsRandomized trialsSuch therapyMineral densitySkeletal fracturesAbsolute reductionEnd pointStudy of hormonesWomenHealth careTrialsAgeTrue declineRisk